D-Cycloserine supported exposure in panic disorder
- Conditions
- Panic disorder agoraphobia
- Registration Number
- EUCTR2006-004860-29-DE
- Lead Sponsor
- Charité- Universitätsmedizin Berlin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 44
Panic disorder and or Agoraphobia
Written informed consent
Age: 18-70 Jahre
Negative pregnancy test and contraception in female subjets
Compliance of the patient
Adequate communication skills
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Other mental disorders like schizophrenia, substance related disorder, Ddmentia
Acute suicidality
Pregnancy and breast feedin
Psychotropic drugs must be stopped at least 3 half lives before
Severe medical disorders,
Prior changes in sleep wake cycle
Starting a cognitive behavioral therapy within the last 3 months
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To show that the additional administration of 50 mg D-Cycloserine increases the clinical effectiveness of exposure therapy in panic diosrder patients as measured with the Panic and Agoraphobia Scale;Secondary Objective: To show that the additional administration of 50 mg D-Cycloserine increases the clinical effectiveness of exposure therapy in panic diosrder patients as measured with the Mobility Inventory, Beck Anxiety Inventory and Hamilton Anxiety Scale.;Primary end point(s): Sum Score of the Panic and Agorphobia Scale
- Secondary Outcome Measures
Name Time Method